Cargando…
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyngeal carcinoma has been mainly empirical. To our knowledge, there is no phase 3 trial that has been conducted to determine the optimal treatment for these patients before our publication. R...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178081/ https://www.ncbi.nlm.nih.gov/pubmed/28007026 http://dx.doi.org/10.1186/s40880-016-0163-6 |